AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |
Back to Blog
Teva 3147 red pill2/2/2024 ![]() Reversible interstitial nephritis has been reported. Other reactions have included hypersensitivity reactions, genital and anal pruritus, genital candidiasis, vaginitis and vaginal discharge, dizziness, fatigue, headache, agitation, confusion, hallucinations, arthralgia, arthritis, and joint disorder. As with penicillins and other cephalosporins, transient hepatitis and cholestatic jaundice have been reported. Nausea and vomiting, dyspepsia, gastritis, and abdominal pain have also occurred. In clinical trials, the most frequent adverse reaction was diarrhea. difficile, and surgical evaluation should be instituted as clinically indicated.īecause clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. CDAD must be considered in all patients who present with diarrhea following antibiotic use. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. difficile produces toxins A and B, which contribute to the development of CDAD. ![]() Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. May be kept for 14 days without significant loss of potency.ĥ.2 Clostridium difficile-Associated DiarrheaĬlostridium difficile -associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including cephalexin, and may range in severity from mild diarrhea to fatal colitis. The resulting suspension will contain cephalexin monohydrate equivalent to 250 mg cephalexin in each 5 mL (teaspoonful). For ease in preparation, tap bottle to loosen powder, add the water in 2 portions, shaking well after each addition. Add to the bottle a total of 140 mL of water. The resulting suspension will contain cephalexin monohydrate equivalent to 250 mg cephalexin in each 5 mL (teaspoonful).Ģ50 mg per 5 mL (200 mL when mixed): Prepare suspension at time of dispensing. Add to the bottle a total of 71 mL of water. The resulting suspension will contain cephalexin monohydrate equivalent to 125 mg cephalexin in each 5 mL (teaspoonful).Ģ50 mg per 5 mL (100 mL when mixed): Prepare suspension at time of dispensing. The resulting suspension will contain cephalexin monohydrate equivalent to 125 mg cephalexin in each 5 mL (teaspoonful).ġ25 mg per 5 mL (200 mL when mixed): Prepare suspension at time of dispensing. FULL PRESCRIBING INFORMATION: CONTENTS * 1 INDICATIONS AND USAGE 1.1 Respiratory Tract Infections 1.2 Otitis Media 1.3 Skin and Skin Structure Infections 1.4 Bone Infections 1.5 Genitourinary Tract Infections 1.6 Usage 2 DOSAGE AND ADMINISTRATION 2.1 Adults and Pediatric Patients at Least 15 Years of Age 2.2 Pediatric Patients (over 1 year of age) 2.3 Dosage Adjustments in Adult and Pediatric Patients at Least 15 Years of Age with Renal Impairment 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 Hypersensitivity Reactions 5.2 Clostridium difficile-Associated Diarrhea 5.3 Direct Coombs’ Test Seroconversion 5.4 Seizure Potential 5.5 Prolonged Prothrombin Time 5.6 Development of Drug-Resistant Bacteria 6 ADVERSE REACTIONS 6.1 Clinical Trials Experience 7 DRUG INTERACTIONS 7.1 Metformin 7.2 Probenecid 7.3 Interaction with Laboratory or Diagnostic Testing 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy 8.2 Lactation 8.4 Pediatric Use 8.5 Geriatric Use 8.6 Renal Impairment 10 OVERDOSAGE 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.3 Pharmacokinetics 12.4 Microbiology 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 16 HOW SUPPLIED/STORAGE AND HANDLING 17 PATIENT COUNSELING INFORMATION * Sections or subsections omitted from the full prescribing information are not listed.ġ25 mg per 5 mL (100 mL when mixed): Prepare suspension at time of dispensing.
0 Comments
Read More
Leave a Reply. |